Abstract
Indolent B-cell lymphoma (iBCL) represents a group of mature B-cell clonal proliferative disorders that frequently involve the peripheral blood and bone marrow. In light of the fifth edition of the World Health Organization (WHO) classification of haematolymphoid tumors published in 2022, some changes have been introduced in the classification and nomenclature of certain iBCL subtypes. Accordingly, in this consensus, the disease spectrum of iBCL was reclassified based on the 2022 WHO framework. Reflecting this update, the Chinese expert consensus on the diagnosis of B-cell chronic lymphoproliferative disorders has been formally renamed as expert consensus on the diagnosis and differential diagnosis of indolent B-cell lymphomas in China. This consensus has been revised by the Hematological Oncology Committee of China Anti-Cancer Association, Lymphoid Disease Group, Chinese Society of Hematology, Chinese Medical Association, and Chinese Working Group for indolent lymphoma, following extensive discussions among domestic experts in hematologic oncology and pathology, with the goal of aligning with current clinical practice.